BBIO
BridgeBio Pharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BBIO
Bridgebio Pharma, Inc.
A commercial-stage biopharmaceutical company focused on genetic diseases and cancers
3160 Porter Drive, Suite 250, Palo Alto, CA 94304
--
BridgeBio Pharma, Inc., was incorporated in Delaware on May 17, 2019. The Company is a commercial-stage biopharmaceutical company that aims to discover, create, test and deliver transformative medicines to treat patients with hereditary diseases and cancers with clear genetic drivers.
Earnings Call
Q3/2025
Estimate EPS-0.78
Actual EPS-0.95
Estimate Revenue106.05M
Actual Revenue120.70M
BridgeBio Pharma's Q3 2025: Contradictions Emerge on Attruby Market Share, Positioning, and Infigratinib Expansion
Oct 30,2025 12:16
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BBIO has released its 2025 Q3 earnings. EPS was reported at -0.95, versus the expected -0.78, missing expectations. The chart below visualizes how BBIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BBIO has released its 2025 Q3 earnings report, with revenue of 120.70M, reflecting a YoY change of 4318.01%, and net profit of -184.94M, showing a YoY change of -12.59%. The Sankey diagram below clearly presents BBIO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
